GlaxoSmithKline (GSK)'s New Smelly Drug Is An Utter Stinkbomb
4/1/2014 8:40:02 AM
Usually, saying that an experimental medicine stinks is a metaphorical statement. You know, its efficacy is marginal, or there are serious side effects. Not so for GlaxoSmithKline's GSK -0.39% darapladib, results of which were presented at the annual meeting of the American College of Cardiology and published in the New England Journal of Medicine yesterday.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by